비티젠, 850억 정책자금 후 숙제…후속 수주에 쏠린 눈

BTGEN’s successful acquisition of large-scale policy funding marks a critical shift towards scaling its manufacturing capabilities, but the real test lies in diversifying its client base beyond internal affiliates. As the global Biosimilar market becomes increasingly competitive, securing high-volume external CMO contracts will be essential to justify the capital expenditure and mitigate existing debt risks.